Abstract
New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We review the incidence, possible mechanisms, significance and management of hypertension in patients treated with VSP inhibitors.
Original language | English (US) |
---|---|
Article number | 6 |
Journal | Cardio-Oncology |
Volume | 1 |
Issue number | 1 |
DOIs | |
State | Published - Dec 2015 |
Externally published | Yes |
Keywords
- Cardiotoxicity
- Hypertension
- Tyrosine kinase inhibitor
- Vascular endothelial growth factor
- VEGF
- VEGF signal pathway inhibitors
- VSP inhibitors
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Oncology